Tagged with EG

Malaysia After 61 years of single-party rule, the May 2018 electoral victory of the populist Pakatan Harapan (PH) coalition sent shockwaves through the Malaysian political landscape. This has been keenly felt within the healthcare sphere, where industry players are broadly supportive of PH’s plans to increase low-income Malaysians’ access to treatments…

India Dilip Shah, the Secretary-General of the Indian Pharmaceutical Alliance advocates for a stronger and more empowered regulator in India if the country is to build public confidence in its pharma output and drug inspectors.    Improving the image of drug inspectors- will require investments in “infrastructure”. The key elements of this…

China Jack Wang, founder and CEO of Biomobie, shares the inspirational story behind the establishment of the company, the regenerative principle driving the technology of the Bioboostie device, and the innovative commercial partnerships he has established with leading health insurance companies in China.   My medical knowledge is limited. But I…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…

Egypt The Egyptian pharma market grew at a compound annual growth rate (CAGR) of 17 percent between 2011 and 2017 to reach a total market valuation of EGP 50 billion in 2017. Low levels of healthcare insurance penetration mean that pharma sales are predominantly driven by out-of-pocket expenditure.   The top…

Egypt Egypt continues to struggle with fake drugs reaching the hands of patients as the suppliers of counterfeit medicines become more sophisticated by adding company logos to packaging.   The Egyptian police have launched large-scale surveillance campaigns aimed at “Bir Al-Salam factories” which are known for manufacturing these drugs that include multiple unknown…

Egypt The Health Committee of the Egyptian House of Representatives is preparing to discuss a draft law from the government on the establishment of the “Egyptian Drug Authority.”   The new entity will specialise in all medicine-related issues, from pricing to shortages to registering new drugs.   Similarly to Europe’s European Medicine…

China Andras Gizur, president China & APAC for Gedeon Richter, shares his insights on the current market environment in China following the spate of recent healthcare reforms, the exciting innovations Gedeon Richter plans to launch in China in the next few years, the importance of fostering a friendly, cooperative and stable…

Egypt Egypt has found a way to profit from the country’s access to cheap Hep C drugs by offering package holidays to tourists suffering from the disease, but the ‘tour and cure’ model raises numerous questions.   Egypt has a long history struggling with Hepatitis C (HCV) that started in the…

Egypt With the highest rate of Hepatitis C on the planet, Egypt is now making great efforts to eradicate the disease in the north MENA regions. Hep C is a disease that costs the country thousands of lives and millions of dollars.     Egypt is believed to have the largest prevalences…

Korea The administration of President Moon Jae-in is moving to ensure the enduring success of South Korea’s healthcare and life sciences industries through increased international collaboration. However, some pharma insiders are calling for even greater governmental support for what is still a tightly regulated sector facing pressures over pricing, exacerbated partly…

Korea Narihiko Yoshii, president of Mitsubishi Tanabe Pharma Korea unveils the value that they are bringing to Korean patients by utilising legislation regarding orphan drugs to fast track the market entry of their products. Yoshii also provides his assessment of how low drug pricing is indirectly affecting the decisions of Mitsubishi…